
BBIO Stock Forecast & Price Target
BBIO Analyst Ratings
Bulls say
BridgeBio Pharma has demonstrated a strong financial outlook, with an updated full-year 2026 revenue forecast projected to rise to $766.3 million, reflecting positive momentum from its late-stage pipeline. The company is positioned for potential regulatory approvals for key candidates ribitol and encaleret in the first half of 2026, driven by robust clinical data suggesting an accelerated review process and favorable pricing opportunities. Additionally, the increase in the likelihood of approval for infigratinib in achondroplasia to 80% indicates a solid pipeline that could further enhance future revenue streams.
Bears say
BridgeBio Pharma's projected net loss for the full year 2025 stands at $3.59, indicating significant financial strain, particularly in the face of potential clinical and commercial setbacks that threaten its operational sustainability. The company is currently burdened by limited cash reserves and substantial debt, raising concerns about its ability to repay lenders and maintain operations in the event of unfavorable trial outcomes. Furthermore, competitive pressures in the market, especially with potential generic alternatives to its key treatment, Attruby, could significantly hinder revenue generation and market penetration.
This aggregate rating is based on analysts' research of BridgeBio Pharma Inc and is not a guaranteed prediction by Public.com or investment advice.
BBIO Analyst Forecast & Price Prediction
Start investing in BBIO
Order type
Buy in
Order amount
Est. shares
0 shares